Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna Amela Valsecchi
Observed names:
A.A. Valsecchi,
Anna A Valsecchi,
Anna A. Valsecchi,
Anna Valsecchi
Institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
University of Turin
Observed institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
A. O. Ordine Mauriziano di Torino,
Candiolo Cancer Institute,
University of Turin
ORCID:
0009-0007-4940-5761
Observed ORCID:
0009-0007-4940-5761
OpenAlex ID:
A5077112642
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024
·
Brigida Anna Maiorano
, Massimo Di Maio
, et al.
·
JAMA Network Open
·
67
Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
2023
·
Anna Amela Valsecchi
, Rossana Dionisio
, et al.
·
Cancers
·
46
PDF
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
2022
·
Margherita Turinetto
, Anna A. Valsecchi
, et al.
·
International Journal of Molecular Sciences
·
39
PDF
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review
2025
·
Anna Amela Valsecchi
, Massimo Di Maio
·
Pharmaceutical Medicine
·
13
PDF
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges
2025
·
Pietro Paolo Vitiello
, Anna Amela Valsecchi
, et al.
·
Cancers
·
12
PDF
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
2022
·
Lucia Musacchio
, Anna Amela Valsecchi
, et al.
·
Cancer Treatment Reviews
·
11
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
2021
·
Giulia Scotto
, Fulvio Borella
, et al.
·
Cells
·
10
PDF
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies
2024
·
M.C. Cursano
, A.A. Valsecchi
, et al.
·
ESMO Open
·
8
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
2024
·
Vittorio Fusco
, Massimo Di Maio
, et al.
·
Supportive Care in Cancer
·
8
PDF
Management of cancer treatment–induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey
2024
·
Anna Amela Valsecchi
, Vittorio Fusco
, et al.
·
Tumori Journal
·
7
Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients
2024
·
A.A. Valsecchi
, V. Battista
, et al.
·
ESMO Real World Data and Digital Oncology
·
7
PDF
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
2022
·
Gaia Giannone
, Daniele Castaldo
, et al.
·
Frontiers in Oncology
·
7
PDF
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project
2024
·
Anna Amela Valsecchi
, Filippo Giovanardi
, et al.
·
The Breast
·
6
PDF
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan
2025
·
Anna Amela Valsecchi
, Simona Pisegna
, et al.
·
The Oncologist
·
4
PDF
Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications
2024
·
Anna Amela Valsecchi
, Giorgia Ferrari
, et al.
·
Critical Reviews in Oncology/Hematology
·
4
PDF
Press releases of industry-sponsored clinical trials in oncology: Characteristics, timing and financial impact
2025
·
Anna Amela Valsecchi
, Cecilia Conte
, et al.
·
Journal of Cancer Policy
·
3
MA14.13 Analysis of Lung Cancer-Specific Patient-Reported Outcome Measures (PROMs): Results from the PRO4All Project
2024
·
A. Servetto
, F. Malandrini
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis)
2026
·
Anna Amela Valsecchi
, Sara Elena Rebuzzi
, et al.
·
Clinical Genitourinary Cancer
·
1
Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review
2025
·
Anna Amela Valsecchi
, Maria Concetta Cursano
, et al.
·
Clinical Genitourinary Cancer
·
1
PDF
535P Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
2024
·
A. Boccaccino
, M. Frapoli
, et al.
·
Annals of Oncology
·
1
PDF
Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin
2022
·
Anna Amela Valsecchi
, Jessica Paparo
, et al.
·
Tumori Journal
·
1
Global management of drug–drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist
2026
·
Anna Amela Valsecchi
, Michele Maffezzoli
, et al.
·
The Oncologist
PDF
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group
2026
·
Anna Amela Valsecchi
, Michele Maffezzoli
, et al.
·
Cancer and Metastasis Reviews
PDF
First-line immune checkpoint inhibitors in elderly colorectal cancer patients in the real world: Retrospective phase of the multicenter ELDER CRC trial.
2026
·
Martina Cassaniti
, Alessandra Boccaccino
, et al.
·
Journal of Clinical Oncology
Patient-reported financial toxicity within Italian public healthcare system: A cross-sectional analysis in patients with cancer
2026
·
Anna Amela Valsecchi
, Pamela Festa
, et al.
·
Tumori Journal
Show more works
View as search
Works count:
34
Citation count:
258
H-index:
8
I10-index:
7
Year
Topic
Type